c-MET anticorps (pTyr1003) (AbBy Fluor® 680)

N° du produit ABIN5006788

L’anticorps Lapin Polyclonal anti-c-MET a été validé pour WB. Il convient pour détecter c-MET dans des échantillons de Humain, Souris et Rat.

Aperçu rapide pour c-MET anticorps (pTyr1003) (AbBy Fluor® 680) (ABIN5006788)

Antigène: c-MET (MET) (Met Proto-Oncogene (MET))

Reactivité: Humain, Souris, Rat

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp c-MET est conjugé à/à la AbBy Fluor® 680

Application: Western Blotting (WB)

Détail du produit anti-c-MET anticorps (AbBy Fluor® 680)

Épitope: pTyr1003

Réactivité croisée: Humain

Homologie: Mouse,Rat,Dog,Cow,Sheep,Pig,Horse,Rabbit,Guinea Pig

Purification: Purified by Protein A.

Immunogène: KLH conjugated synthetic phosphopeptide derived from human c-Met around the phosphorylation site of Tyr1003

Isotype: IgG

Information d'application

Indications d'application: IF(IHC-P) 1:50-200

Restrictions: For Research Use only

Stockage

Format: Liquid

Concentration: 1 μg/μL

Buffer: Aqueous buffered solution containing 0.01M TBS ( pH 7.4) with 1 % BSA, 0.03 % Proclin300 and 50 % Glycerol.

Stock: -20 °C

Stockage commentaire: Store at -20°C. Aliquot into multiple vials to avoid repeated freeze-thaw cycles.

Date de péremption: 12 months

Détails sur c-MET

Antigène: c-MET (MET) (Met Proto-Oncogene (MET))

Autre désignation: Met c-Met

Sujet:

Synonyms: Met c-Met Tyr1003, AUTS9, c met, cmet, D249, Hepatocyte growth factor receptor, Hepatocyte growth factor receptor Precursor, HGF, HGF receptor, HGF SF receptor, HGF/SF receptor, HGFR, MET, Met proto oncogene tyrosine kinase, Met proto-oncogene hepatocyte growth factor receptor, Met proto-oncogene, Met protooncogene, MET_HUMAN, Oncogene MET, Par4, Proto-oncogene c-Met, RCCP2, Renal cell carcinoma papillary 2 gene, Scatter factor receptor, SF receptor, Tyrosine-protein kinase Met.

Background: c-Met, a member of the tyrosine kinase superfamily, is the receptor for hepatocyte growth factor, also known as scatter factor (HGF/SF). The mature c-Met protein is a disulfide-linked heterodimer with Mr=190 kDa composed of a heavily glycosylated alpha subunit that is completely extracellular in localization, and a beta subunit comprising an extracellular ligand binding domain, a single transmembrane domain, and a cytoplasmic tyrosine kinase domain. Cells expressing c-Met include epithelial cells, endothelial cells, blood cells of various types, and glomerular mesenchymal cells.HGF/SF binding to c-Met stimulates receptor dimerization and the phosphorylation of numerous residues within the receptor?????s cytoplasmic domain. Signaling proteins that are phosphorylated and/or localized in response to c-Met phosphorylation include: Grb2, Shc, Cbl, Crk, cortactin, paxillin, GAB1, PI3K, FAK, Src, Ras, ERK1 and 2, JNK, PLC gamma, AKT, and STAT3. HGF/SF stimulation of c-Met expressing cells enhances proliferation, migration, morphogenesis, and protease synthesis, characteristics that are associated with invasive cell phenotype. Many types of cancer exhibit sustained c-Met stimulation, overexpression, or mutation, including carcinomas of the colon, breast, ovary, lung, liver, prostate, thyroid, kidney, as well as melanomas and sarcomas. In addition to cancer studies, other research areas in which c-Met is under investigation include organogenesis, organ regeneration, angiogenesis and surgical wound healing.

ID gène: 4233

Pathways: Signalisation RTK, Carbohydrate Homeostasis, Synaptic Membrane, Signaling of Hepatocyte Growth Factor Receptor